Five-year relative survival for malignant breast cancer in the U.S: A population-based study using SEER 12, 1992–2015

Author

AMF

Published

January 24, 2024

Modified

February 6, 2024

Ratinale

Our main goal is to evaluate the 5-year relative survival for malignant breast cancer by subtype, and investigate the extent to which survival differences among the major racial and ethnic groups have progressed over the span of nearly three decades, from 1992 to 2020.

Methods

Figure A presents the annual proportions of breast cancer cases with unknown ER status. Figure B details the yearly proportions of breast cancers with ER-negative status.”

Total number of cases included 1626352. The first exclusion criterion—applied was the exclusion of death certificate and autopsy cases 14,324 (0.6%). Than, 361,260 cases, representing 22.2% of the selected cases, were excluded for being subsequent primary occurrences (Sequence Number higher than 1) rather than first primary cancer instances. Lastly, 2,734 cases (0.2%) were removed due to being alive with no survival time recorded.

Case Exclusion Counts
Number Selected Number Excluded Statement Proportion Excluded
2323651 2918834 {Age at Diagnosis...} = '35-39 years', '40-44 years'... 125.6
2309327 14324 Exclude death certificate or autopsy cases 0.6
1990346 318981 Select only malignant cancers 16.0
1990346 0 Select only known age 0.0
1990346 0 Exclude age values not in table 0.0
1990346 0 Exclude Race and origin recode values not in table 0.0
1990346 0 Exclude Sex values not in table 0.0
1990346 0 Exclude State values not in table 0.0
1990346 0 Exclude County values not in table 0.0
1629086 361260 First Primary Only (Sequence Number 0 or 1) 22.2
1629086 0 Invalid vital status 0.0
1629086 0 Unknown survival duration 0.0
1629086 0 Calculation dates invalid 0.0
1629086 0 Coded survival duration conflicts... 0.0
1629086 2734 Alive with no survival time 0.2
1626352 0 Cases for which an expected rate could not be found 0.0

Results

Analysis of 5-Year Age-Standardized Net Survival by Breast Cancer Subtype (2010-2020)

Figure 4. 5-Year Age-Standardized Net Survival by Breast Cancer Subtype (2010-2020)

Estimated annual percentage change (EAPC) in 5-year age-adjusted net survival

Figure 6. 5-Year Age-Adjusted Net Survival by Race, Ethnicity, and Cancer Stage

EAPC with  95 % CI level have been computed
Annual Percent Change
race stage apc eapc_up eapc_low
NHW Localized 0.0632228 0.6457773 -0.5159598
NHW Regional 0.5099972 1.1396866 -0.1157719
NHW Distant 2.4263695 3.5584197 1.3066943
NHB Localized 0.3152329 0.9123383 -0.2783395
NHB Regional 1.1070423 1.7914545 0.4272320
NHB Distant 2.1153695 3.5258697 0.7240868
API Localized 0.0414952 0.6279400 -0.5415318
API Regional 0.3930158 1.0341732 -0.2440728
API Distant 2.9525179 4.1502866 1.7685239
HIS Localized 0.1389664 0.7319316 -0.4505084
HIS Regional 0.5295265 1.1758132 -0.1126319
HIS Distant 2.1883767 3.3310755 1.0583146

Discussion

Bullet Points

  • Interestingly, our preliminary analysis of the 5-year relative survival (SEER22) for HR+/HER2- breast cancer suggests much lower survival rates for the NBH population, particularly at the regional and distant stages.

  • I was speculating whether some of these differences in survival could, in part, reflect variabilities in chemotherapy patterns among populations (as discussed in the article) and also some of the community-level health factors, such as poverty and the socioeconomic status (SES) index.

References: